NASDAQ:EXEL 17 August 2025

Senolytic Drugs
··········

The Secret “Zombie Cell” Killers: Niche Senolytic Drugs Fighting Aging’s Clock

A Mayo Clinic-led Phase 2 trial published July 2024 found dasatinib plus quercetin modestly increased wrist bone density in older women with high senescent-cell burden. Unity Biotechnology’s foselutoclax improved vision in diabetic macular edema patients after a single injection. About 20 senolytic clinical trials are underway worldwide, with Alzheimer’s disease results expected in 2025.
August 17, 2025

Stock Market Today

  • Can Bank of Queensland Shares Outperform ASX 200 by 2026?
    May 28, 2026, 5:26 PM EDT. Bank of Queensland (ASX: BOQ) trades at a price-to-earnings (PE) ratio of 15.1x, below the banking sector average of 18x, suggesting it may be undervalued. Using BOQ's fiscal 2024 earnings per share of $0.41 and sector-average PE, a sector-adjusted valuation estimates the share price at $7.30, above the current $6.18. Analysts suggest the dividend discount model (DDM), which values shares based on expected dividends and risk rates, offers a more refined assessment. With dividends and growth projections critical to DDM outputs, cautious investors should weigh these alongside market risks. While BOQ's shares show potential to outperform the S&P/ASX 200, no valuation guarantees future returns. Investors should consider sector dynamics and risk factors ahead of 2026.